Fortrea Holdings Inc. reports news on its role as a global contract research organization serving the life sciences industry. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services for biopharmaceutical, biotechnology, medical device and diagnostic customers.
Recurring Fortrea updates include quarterly and annual financial results, book-to-bill trends, guidance, debt and capital actions, executive and board matters, equity award disclosures and technology used in clinical trial operations. Company announcements also cover platforms such as Fortrea Intelligent Technology and Xcellerate, which support trial workflow, oversight and site-facing processes.
Fortrea (Nasdaq: FTRE) announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP Investor Relations Tracy Krumme will participate in two December healthcare conferences in Miami.
Details: Citi Global Healthcare Conference — Tuesday, December 2, 2025 at 1:00 pm ET (fireside chat, webcast). Evercore 8th Annual Healthcare Conference — Wednesday, December 3, 2025 at 10:50 am ET (fireside chat, webcast).
Live webcasts and replays will be available in the Events section of Fortrea’s Investor Relations website. Investors seeking one-on-one meetings should contact their banking representatives.
Fortrea (Nasdaq: FTRE) completed a tender offer, purchasing $75,743,000 aggregate principal of its 7.500% Senior Secured Notes due 2030 on November 21, 2025.
The repurchase reduced principal outstanding on the Notes from $570,000,000 to $494,257,000. The company said it funded the transaction entirely with cash on hand and that the Tender Offer satisfied a requirement related to its June 2024 divestiture of Fortrea Patient Access and Endpoint Clinical businesses.
U.S. Bank Trust reported that valid tenders exceeded $75,744,000; Fortrea accepted $75,743,000 based on a Final Proration Factor of 0.154199 and rounding rules.
Fortrea (Nasdaq: FTRE) announced on November 17, 2025 the appointment of Agnieszka M. Gallagher as general counsel. Gallagher will lead the company’s legal strategy and operations, serve as corporate secretary and chief compliance officer, and join Fortrea’s leadership team.
Gallagher brings more than 25 years of experience across life sciences, biotech, diagnostics, pharmaceutical and medtech sectors, including roles as chief legal officer at Standard Biotools where she was involved in its merger with SomaLogic, and senior legal and compliance positions at Orasure, Alnylam, ViiV Healthcare, GSK Biologics, Sandoz, Medtronic and Pfizer. She succeeds J. Stillman Hanson, who is leaving after a planned transition period.
Fortrea (Nasdaq: FTRE) reported third-quarter 2025 continuing-operations results with Q3 revenue of $701.3M and a Q3 adjusted EBITDA of $50.7M. GAAP net loss for the quarter was $15.9M and adjusted net income was $11.7M (diluted EPS $0.12). Backlog stood at $7,644M and book-to-bill was 1.13x. Year-to-date revenue was $2,062.9M, while YTD GAAP net loss was $953.7M, which included a $797.9M non-cash goodwill impairment impacting EPS by $8.81. The company raised full-year 2025 revenue guidance to $2,700M–$2,750M and narrowed adjusted EBITDA guidance to $175M–$195M.
Management said cost-saving initiatives remain on track and there were no impairment indicators in Q3.
Fortrea (Nasdaq: FTRE) commenced a cash tender offer to purchase up to $75,744,000 aggregate principal of its outstanding 7.500% Senior Secured Notes due 2030, effective October 20, 2025. The offer price is $1,000 per $1,000 principal plus accrued interest; the Tender Offer will expire at 5:00 p.m. New York time on November 18, 2025 unless extended.
The principal purpose is to comply with indenture covenants tied to net proceeds from Fortrea’s June 2024 divestiture; funding is expected from cash on hand and/or other liquidity sources. Acceptance is subject to conditions and possible proration. Holders may withdraw tenders prior to expiration.
Fortrea (Nasdaq: FTRE) will release its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. The company will host a conference call at 8:00 am ET that day to review results and hold a Q&A session.
Participants must register on the Fortrea Investor Relations website and are advised to join at least 10 minutes early to avoid delays. The call will be available via an earnings webcast, and a replay will be posted shortly after the event in the events and presentations section of the Fortrea Investor Relations website.
Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has announced the appointment of William Sharbaugh to its Board of Directors. Sharbaugh brings over three decades of pharmaceutical industry experience with expertise in finance, operations, manufacturing, and quality.
CEO Anshul Thakral highlighted Sharbaugh's extensive background in CRO and pharmaceutical operations, emphasizing his understanding of stakeholders and global drug development. Sharbaugh expressed his commitment to leveraging his dual experience in CRO and pharmaceutical companies to create value for all stakeholders.
Fortrea (Nasdaq: FTRE), a global contract research organization, has announced the granting of inducement awards to a new employee. The award consists of 75,000 restricted stock units (RSUs) that will vest over three years in equal annual installments, beginning September 12, 2026.
The RSUs are granted under the Company's Amended and Restated 2025 Inducement Award Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an employment inducement for the new hire.
Fortrea (Nasdaq: FTRE), a leading contract research organization (CRO), reported its Q2 2025 financial results with revenues of $710.3 million, up from $662.4 million in Q2 2024. The company posted a GAAP net loss of $(374.9) million, largely due to a $309.1 million non-cash goodwill impairment charge.
Key highlights include adjusted EBITDA of $54.9 million and adjusted earnings per share of $0.19. The company reported a book-to-bill ratio of 0.79x for Q2, with a trailing 12-month ratio of 1.10x. Fortrea raised its 2025 revenue guidance to $2,600-$2,700 million while affirming adjusted EBITDA guidance of $170-$200 million.
The company welcomed Anshul Thakral as CEO on August 4, 2025, succeeding Interim CEO Peter M. Neupert, who remains chairman of the Board.
Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has appointed Tracy Krumme as Senior Vice President of Investor Relations, replacing Hima Inguva. Reporting to CFO Jill McConnell, Krumme will lead the company's global investor relations strategy.
Krumme brings over 30 years of experience in investor relations and capital markets, with significant expertise in the CRO, life sciences, and healthcare sectors. Her previous roles include head of investor relations at PPD (acquired by Thermo Fisher Scientific), Galderma, and Nuance Communications (acquired by Microsoft). She has worked alongside Fortrea's current CEO Anshul Thakral during her tenure at PPD.